Our work sheds light on the importance of CXCR3 and CCL18 as the essential markers of immunogenic cell death in HCC, which could be served as biomarkers of prognosis and immunotherapy efficacy in the future. This evidence concerns the gene CCL18 and hepatocellular carcinoma.